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METHODS FOR BIOMOLECULE AND 
BIOMOLECULE COMPLEX (BMC) 
DETECTION AND ANALYSIS AND THE USE 
OF SUCH FOR RESEARCH AND MEDICAL 
DIAGNOSIS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application is related to U.S. Provisional Application 
No. 61/294,877; filed Jan. 14, 2010 and U.S. Provisional 
Application 61/407,038 filed Oct. 27, 2010, and to which 
priority is claimed under 35 USC §119. 
INTRODUCTION 
Biomolecular interactions such as protein-protein and pro-
tein-DNA interactions play an essential role in almost all 
cellular functions. Many intracellular biochemical processes 
are triggered by the assembly of biomolecules including pro-
teins, DNAs and RNAs into biomolecule complexes (BMC), 
providing a means to control the myriad of biochemical pro-
cesses for the efficient management of vital biological 
responses. The detection and analysis of these biomolecule 
complexes is not only critical for understanding the mecha-
nisms of diseases, but also provide new methods and 
approaches for diagnosis and treatment of the diseases. 
2 
assay solution. The particle size increase of the assay solution 
was then monitored and used to identify the binding partner. 
(B) Kinetic binding assay of EGFR-AuNP probe for mouse 
IgGl-AuNP probe was used as a negative isotype control to 
5 the EGFR-AuNP probe) with EGFRprotein and its complex 
from a pancreatic cancer cell line, Pane-I nuclear extracts. 
(C) and (D) Protein complex binding partner analysis 
whereby the polyclonal anti-Stat3, anti-Src or anti-EGFR 
antibody or the non-specific rabbit IgG (negative control) is 
10 added to the assay solution prepared from the anti-EGFR-
AuNP probe (C) or non-specific mouse IgGl-AuNP probe 
(negative control) (D). Data are representative of 4 indepen-
dent studies. 
FIG. 5 (A) An illustration of gold nanoparticle immuno-
15 probe cluster formation due to their binding with protein 
complexes or aggregates. (B) From the nonlinear dose-re-
sponse curve, the concentration at which substantial GAPDH 
protein aggregation appears is identified. (C) and (D) The 
particle size distribution curves of the GAPDH assay solution 
20 at 25 and 50 µg/mL, respectively. 
FIG. 6 (A) The size distribution curves of assay solutions 
from a normal prostate, prostate adenocarcinoma, and benign 
prostate hypertrophy (BPH) tissue lysate sample. Data pre-
sented in each graph are intensity distribution curves of an 
25 assay solution from ten measurements. (B) The polydisper-
sity index (PdI) of the assay solutions from each sample. The 
numbers on top of the prostate cancer sample data are the 
Gleason sum score of the tissues. All data presented here are While a large number ofbioanalytical techniques exist for 
detecting and analyzing the concentrations of individual bio-
molecules, techniques available for studying biomolecular 30 
interactions and for biomolecule complex detection and 
analysis are rather limited and inadequate to meet the 
demands and challenges ofbiomolecular research and medi-
the average often measurements. 
FIG. 7 Mouse serum protein adsorption study and target 
protein analysis. Data are particle size increases of the assay 
solution of: (A) undiluted mouse serum adsorbed to AuNPs; 
(B) IgG assay of 10-fold diluted mouse serum; (B) VEGF 
assay of 10-fold diluted mouse serum. For each assay, 40 µL cal diagnosis. Many traditional techniques such as co-immu-
noprecipitation, immunoaffinity chromatography, and yeast 
two-hybrid assays involve complicated assay procedures, 
require a large volume of samples (1 OOs µL ), and take hours 
to days to obtain the results. Furthermore, these traditional 
techniques can only reveal the identities of the binding part-
ners, and are not capable of providing the kinetic binding 
information. More recent techniques, such as fluorescence-
based techniques and surface plasmon resonance (SPR) 
enable both detection and kinetic binding study of biomo-
lecular interactions and complex formation, but have limita-
tions, such as labeling, that may affect or destroy the structure 
and binding activity of the biomolecules, or in the case of 
SPR, theneedfor a solid-phase based technique (not solution-
based assay) and the high cost. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows a schematic of a first embodiment of a target 
molecule detection system. 
FIG. 2 shows a schematic of a second embodiment of a 
target molecule detection system. 
FIG. 3 shows a schematic of a third embodiment of a target 
molecule detection system. 
35 of AuNP solution was mixed with 2 µL of serum sample. After 
certain incubation time, an appropriate amount of anti-mouse 
IgG or anti-VEGF was added to the assay solution to analyze 
the level of IgG or VEGF adsorbed to AuNPs. 
FIG. 8 VEGF assay results of 10-fold diluted (A) and 
40 undiluted (B) human serum samples from cancer and non-
cancerous donors. The non-cancerous donors include normal 
and BPH patients. 40 µL of AuNP solution was mixed with 2 
µL of serum sample. After certain incubation time, 2 µL 
anti-VEGF solution(0.5 mg/mL)was added. The particle size 
45 increase is the size difference measured before and after the 
addition of antibody. In A, the small legends on some samples 
such as Tic are the stage of the prostate cancer. Samples with 
a cancer stage ofT2c or above are labeled with a cyan color. 
The average particle size change of all cancer samples minus 
50 the six early stage cancer samples is zero. 
DETAILED DESCRIPTION 
The present patent application discloses several new meth-
55 ods to detect and analyze biomolecule complexes (BMC) and 
use of such for medical diagnosis. For the purpose of this 
application, biomolecule complex is defined as one biomol-
ecule subunit such as proteins, DNAs, RNAs, carbohydrates 
bound with at least another biomolecule through covalent or 
FIG. 4. (A) An illustration of an assay for protein complex 
detection and binding partner analysis from a cell nuclear 
extract. The assay was comprised of two steps: in the first 
step, AuNP immunoprobe for one target protein, here is 
EGFR, is mixed with a sample solution. The particle size 
increase caused by the binding of EGFR protein or protein 
complex to AuNP probes is monitored. After the binding 
event reaches an end point, the assay solution was divided into 65 
multiple portions and to each portion, a polyclonal antibody 
for each suspected protein binding partner was added to the 
60 non-covalent chemical bonding. An individual biomolecule 
or biomolecule subunit is defined as a monomer. Further-
more, two types of biomolecule complexes are specifically 
exemplified here: one is heterogeneous complex made from 
one biomolecule and at least another different biomolecule, 
and a second one is a homogenous complex made from at 
least two same biomolecules or biomolecule subunits. Also 
for the purpose of this application, each molecule component 
US 9,005,994 B2 
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in the complex is defined as "binding partner". This applica-
tion mainly uses proteins as an example of biomolecules, 
however, the methods disclosed here can be applied for any 
other types of biomolecule complexes such as protein-DNA, 
protein-RNA, DNA-DNA, DNA-RNA complexes. Naturally, 
the embodiments disclosed herein may be used to detect 
biomolecules that are not complexed or aggregated. 
4 
value of X. In this case, the obtained size information of 
molecule X can be used to deduce the complex status and 
level of molecule X. 
For the purpose of this application, nanoparticles in this 
application refer to particles with a diameter ranging from 1 
nm to 10,000 nm, preferably 1-1000 nm. The new methods 10 
and system embodiments disclosed herein are an extension of 
the ground breaking work disclosed in PCT/US09/30087; 
filed Jan. 5, 2009. 
As a variation to this embodiment, the same nanoparticle 
could contain more than one type of baiting molecules for 
different target molecules. For example, baiting molecule for 
X and A can be both immobilized on the nanoparticle and 
such nanoparticle can bind with more than one type of target 
molecule from sample solution. 
Furthermore, by adding a second step to the assay, the 
binding partner of the biomolecular complex can be further 
revealed through a screening analysis. After the first step of 
the assay, a solution of baiting molecule that can specifically 
bind with an interested binding partner molecule A will be 
added to the assay solution. The nanoparticles may or may not 
need to be isolated from the rest of the assay solution before 
It should be borne in mind that the type of nanoparticle 
referred in the present patent application is not limited to 15 
metal nanoparticles. The particle size measurement tech-
nique in this application is not limited to dynamic light scat-
tering. Furthermore in some embodiments as described 
below, other detection techniques may be used to detect the 
nanoparticle clustering caused by biomolecular complex 20 
conducting the second step of the assay. If the interested 
potential binding partner A is present on the nanoparticles, the 
binding of the baiting molecule for target molecule A to the 
nanoparticle will cause a further increase of the nanoparticle 
size or nanoparticle cluster formation, therefore, confirming interactions. 
Biological samples that can be tested using the method 
embodiments taught herein include, but are not limited to, are 
tissue, tissue lysates, tissue fluids, cells, cell lystates, cell 
culture media, blood, urine, stool, semen, fluid secreted from 
breast, saliva, sputum, or circulating tumor cells; and/or prod-
ucts derived from the above biological samples after chemi-
cal, physical, or biological treatments. Reference to diseased 
or non-diseased samples herein refers to biological samples 
in or derived from a subject having a disease state or a non-
diseased state, respectively. 
FIGS. 1-3 provide schematics of three embodiments for 
detecting biomolecules. In one embodiment (FIG. 1), the 
invention involves a nanoparticle (preferably gold or silver 
nanoparticle) that is coated with a layer of "baiting" biomol-
ecule. A "baiting molecule" as used herein means a molecule 
that can specifically bind with another biomolecule through 
non-covalent chemical interactions. Antibody is an example 
of"baiting molecule". Single strand DNA is another example 
of a "baiting molecule". The baiting molecule will bind with 
a specific target molecule X in the sample. This baiting mol-
ecule-coated nanoparticle is referred to herein as "nanopar-
ticle probe". By contacting the nanoparticle probe solution 
with a sample solution, a target molecule X and/or its com-
plexes will bind with the nanoparticle probe, causing nano-
particle probe size increase or nanoparticle clustering. Such 
nanoparticle size change in the assay solution can be mea-
sured by dynamic light scattering or other particle size analy-
sis techniques to reveal the presence of target protein or 
protein complexes in the sample solution. The size measure-
ment can be done continuously to reveal the binding kinetics 
as illustrated in the graph in FIG. 1. The binding constant or 
binding energy between the baiting molecule and the target 
molecule or complex can be obtained by fitting the binding 
curve into a Langmuir adsorption model using Langmuir 
equation. When the binding reaches a saturated level, the size 
of the target molecule X and/or its complex may be revealed 
from the average particle size change or particle size distri-
bution change. The particle size change can be used to obtain 
the concentration of molecule X in the sample solution. Fur-
thermore, by designing the assay so that a saturated binding 
between molecule X and the nanoparticle probe is achieved, 
the net increase of the particle size at saturated binding should 
be equal to twice of the diameter (2D) of the target molecule 
that molecule A and molecule X formed a biomolecular com-
plex. 
Alternatively, the method can include the successive expo-
25 sure of the assay solution to baiting molecule for target mol-
eculeA without conducting particle analysis after exposure to 
the nanoparticle probe with the biological sample. Based on 
the particle characteristics, one can determine whether bait-
ing molecule for target molecule A binds to the nanoparticle 
30 probe presumably already having target molecule X bound 
thereto. From this, it can be deduced that the biomolecule 
complex includes target molecule X complexed to target mol-
ecule A. 
In a second embodiment (FIG. 2), the assay is designed so 
35 that same or different nanoparticle probes will bind with a 
biomolecule complex from different sites of the complex to 
form nanoparticle clusters. In the illustration, two nanopar-
ticle probes for two biomolecules X and A are shown. For 
illustration purpose, the complex shown here is a two-mol-
40 ecule complex, but the complex can include as many mol-
ecules as possible. The two nanoparticle probes may be mixed 
simultaneously or sequentially with the sample solution. 
When used simultaneously, the assay will lead to nanoparticle 
dimer or cluster formation if a biomolecule complex XA is 
45 present in the sample solution. The average particle size and/ 
or particle size distribution will provide quantitative informa-
tion on the complexing level of XA. Complexing level can 
mean both concentration of the complex XA and the size of 
the complex. For example, the presence oflarge biomolecule 
50 complex will lead to significant broadening of the particle 
size distribution curve. When used sequentially, either nano-
particle probe may be first mixed with sample solution to 
allow binding of the first biomolecule from the complex to the 
nanoparticle pro be. Then a second pro be is added to detect the 
55 second biomolecule in the complex. More nanoparticle 
probes may be added to the assay solution to detect additional 
binding partners in the complex. 
As a special case of second embodiment, target molecule X 
and A are the same. In this case, biomolecular complex XA 
60 may also be called bimolecular aggregate (or may also be 
referred to as a homogenous complex).A larger aggregate can 
lead to larger particle size increase and/or broadened particle 
size distribution curve after the sample solution is in contact 
with at least one nanoparticle probe solution. 
X. From this analysis, the size of molecule X can be obtained. 65 
If target molecule X formed complexes with other biomol-
ecules, then the nanoparticle size increase will exceed the 2D 
Reference to particle analysis may include, but is not lim-
ited to, determining a particle size change (including an indi-
vidual particle size change), an average particle size change, 
US 9,005,994 B2 
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particle size distribution change, polydispersity change of the 
size distribution, or measurement-to-measurement particle 
size variation, or combinations thereof. In a specific embodi-
ment, particle analysis is conducted via DLS. 
In a third embodiment, a nanoparticle without specific 
baiting molecule attached on the surface is mixed with a 
sample solution. Proteins and/or other biomolecules from the 
sample solution will be non-specifically adsorbed to the 
nanoparticle to form a biomolecule "corona". Gold or silver 
nanoparticles possess a charge that will allow them to non- 10 
specifically adsorb biomolecules. The size of this biomol-
ecule corona, may be determined using dynamic light scat-
tering or other suitable particle size analysis techniques. The 
size of this corona may be used to analyze a biological pro-
cess, determine the disease status or reveal other physiologi- 15 
cal conditions of the sample donor. Furthermore, a second 
step assay may be conducted to reveal and quantify the indi-
vidual biomolecules that are present in the biomolecule 
corona. If a target molecule X is present in the corona, the 
addition of an antibody or baiting molecule for molecule X to 20 
the assay solution will further increase the size of the particle, 
or cause particle cluster formation. Such particle size change 
can be correlated to the concentration or the size of molecule 
6 
this complex functions as a transcript factor to regulate the 
cell growth of Pane- I. An assay based on the first embodiment 
confirmed the existence of such a complex in Pane- I cell 
nuclei. 
A mouse monoclonal antibody, anti-EGFR, was conju-
gated toAuNPto formEGFR-AuNPprobe. Upon mixing this 
probe solution with Pane-I nuclear lysate, the particle size 
increased rapidly from ca. 60 nm to 140 nm, while a non-
specific isotype control mouse IgG I-conjugated to AuNP 
exhibits only about I 0 nm of size increase after the assay 
(FIG. 4B). The rapid increase of the nanoparticle probe size 
corresponds to specific binding of target protein EGFR to the 
probe, while the slow and small size increase of mouse IgG 1-
AuNP probe is indicative of non-specific interactions. 
The net increase of the anti-EGFR-AuNP probes after 
deducting the size increase caused by non-specific interac-
tions, is about 70 nm. This suggests that the size of the EGFR 
protein complex detected by the anti-EGFR-AuNP probe is 
approximately 35 nm. EGFR protein has a molecular mass of 
170 KDa. The size ofEGFR protein alone should be between 
I 0-45 nm. Therefore, data shown in FIG. 4B suggests that the 
EGFR detected by the nanoparticle probe is most likely in a 
complex form. In a second step assay, when a polyclonal 
anti-Stat3 or anti-Src was added to the assay solution, the X in the sample solution. The concentration and/or size infor-
mation of X can be used to analyze a biological process, 
determine the disease status or reveal other physiological 
conditions of the sample donor. Alternatively, if a target mol-
ecule D is not adsorbed to the nanoparticle, then the addition 
of a baiting molecule for Din the assay solution will not cause 
significant change of the nanoparticle size or formation of 
nanoparticle clusters. 
25 nanoparticle size increased further by 30-35 nm; while the 
addition of isotype control rabbit IgG and anti-EGFR caused 
much less nanoparticle size increase (FIG. 4C). The substan-
tial size increase from the addition of anti-Stat3 and anti-Src 
suggests that Stat3 and Src are binding partners in the EGER 
EXAMPLES 
30 complex. The small size increase of the assay solution upon 
addition of anti-EGFR probe is due to the fact that Stat3 and 
Src in the complex blocked the binding sites ofanti-EGFR to 
the nanoparticle-bound EGFR protein. The EGFR/Stat3/Src 
complex was further confirmed by co-immunoprecipitation 
In the following, three examples are given for each of the 
embodiments as described above. Additionally, a fourth 
example is provided to describe how the biomolecular com-
plexes discovered from our research can be used for diagnos-
35 followed by immunoblotting and laser scarming confocal 
microscopic analysis. 
tic applications. 
Co-immunoprecipitation is considered as the gold stan-
dard for protein complex detection from biological samples. 
However such analysis requires a substantial amount of 
I. Detection of a Heterocomplex EGFR/Stat3/Src From a 
Pancreatic Cancer Cell Line, Pane- I Cells 
40 samples (IOOs µL) and the analysis takes hours to days to 
complete. SPR technique also requires I Os- I OOs µL of sample 
per analysis. As a comparison, our new assay requires 1-2 µL 
of lysate samples and results are obtained in minutes. More 
importantly, neither co-immunoprecipitation, nor fluores-
Using the first embodiment (FIG. 1), we recently success-
fully studied the assembly of signaling molecules into com-
plexes that promote signal transduction. In particular, the new 
invention permitted the detection of hitherto unknown het-
erocomplex formed from three proteins: epidermal growth 
factor receptor (EGFR), Stat3, and Src in the nuclei of a 
pancreatic cancer cell line, Pane- I. EGFR is an important 
regulator of cellular responses, including growth and sur-
vival. The attention from biomolecular researchers on EGFR 
protein has been enormous in part because there remains a 
significant gap in the understanding of the key molecular 
partners that serve this pathway and how they contribute to 
the overall associated cellular responses. From the molecular 
and biological perspectives, EGFR is involved in a large 55 
number of sophisticated events that support cellular pro-
cesses. EGFR is found in the plasma membrane, cytosol and 
nuclei of cells. A full understanding of all aspects of the 
EGFR protein, not only its expression level, but also its activ-
45 cence technique, nor SPR is able to reveal the size informa-
tion of the EGFR-Stat3-Src complex. Such information is 
particularly useful for protein complex analysis: it gives the 
first evidence of the presence of a protein complex, and can 
further reveal how many binding partners are involved in a 
50 protein complex. According to the assay results obtained so 
far, we believe the complex involves EGFR, Stat3 and Src 
only, because the estimated hydrodynamic diameter of such a 
triple-component complex according to each protein's size is 
around 35 nm, corresponds to the observed size from the 
assay. 
2. Protein Aggregate Detection and Quantitative Analysis 
Protein aggregate formation is a significant and challeng-
ity regulation, translocation, structural changes and the inter- 60 
actions with other proteins is essential for developing an 
effective model relevant to the functional role of this pathway 
ing problem in biopharmaceutical development. To use pro-
teins as therapeutic agents, they need to be formulated into 
high concentration solutions. Unfortunately, many proteins 
tend to aggregate at high concentrations. Once protein is 
aggregated, it can cause significant adverse effects by chang-
ing the pharmacokinetics of the drug or inducing unexpected 
immunogenicity. Protein aggregation is also closely associ-
ated to many diseases such as prion protein aggregates in 
Creutzfeldt-Jakob disease (CJD) and amyloid ~-protein 
in the overall biological phenotype. A study by J. Turkson et 
al. revealed that concurrent targeting of three proteins, EGFR, 
Stat3 and Src can enhance the therapeutic effect on pancreatic 65 
cancer. It was hypothesized based on their studies that EGFR, 
Stat3 and Src may have formed a heterocomplex nuclei and aggregates found in Alzheimer's disease. However, tech-
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niques that are available for direct detection and analysis of 
protein aggregation are extremely limited, especially for the 
detection of protein aggregates from complex biological 
samples and fluids in the presence of non-target proteins, 
biomolecules, and other colloidal particles. One widely used 
approach is by fluorescence techniques. Fluorescent probes 
are conjugated to the target protein by covalent bonding. 
Upon protein aggregation, fluorescent probe molecules will 
also aggregate, causing fluorescence signal change. A signifi-
cant drawback of the fluorescence techniques is the need to do 1 o 
a fluorescence labeling of the target molecule. Other com-
monly used techniques for protein aggregate detection 
include size exclusion chromatography (SEC) and analytical 
ultracentrifugation. These techniques are only suitable for 
pure protein solution study, not suitable for detection of pro- 15 
tein aggregates and complexes directly from real biological 
samples. 
We have demonstrated that a new assay as illustrated in the 
second embodiment (FIG. 2) can be used as a label-free 
technique for highly sensitive detection of protein aggregates. 20 
In Rayleigh scattering, the scattered light intensity is propor-
tional to the sixth power of the radius (I cxR 6 ) of a particle. 
When protein complexes or aggregates with a non-uniform 
size distribution are present in a sample solution, these com-
plexes/aggregates will load to the formation of large nano- 25 
particle clusters as shown in FIG. SA. The scattered light 
intensity from the large AuNP clusters is thousands to mil-
lions times stronger than individual AuNPs (the detection 
limit for individual AuNPs by DLS can already reach pM-aM 
range). Protein aggregation can be detected with extremely 30 
high sensitivity through the amplification of AuNP probes. 
Results shown in FIG. SB-D are from our study on an enzyme 
GAPDH (glyceraldehyde 3-phosphate dehydrogenase, a pro-
tein used routinely as a loading control in Western Blot analy-
sis). From the assay, we discovered that this protein has a 35 
strong tendency to form large aggregates at a concentration 
around 10-25 µg/mL. The protein aggregate formation leads 
to a non-linear and abnormal nanoparticle size increase 
around this concentration (FIG. SB), and significant broad-
ening or even peak splitting of the size distribution curves 40 
(Compare FIG. SD with FIG. SC). 
Furthermore, by using this new assay, we discovered that a 
cancer biomarker protein, prostatic acid phosphatase (PAP) 
exists more in the form ofbiomolecular complexes in cancer 
tissue than in normal and benign prostate hyperplasia (BPH) 45 
tissue. For this assay, an anti-PAP antibody is conjugated to 
AuNPs to make a nanoparticle immunoprobe. As shown in 
FIG. 6A, the particle size distribution curves from prostate 
cancer tissue lysate assay solution are substantially more 
broadened than BPH samples, and a significant amount of 50 
large nanoparticle clusters appeared at 1 OOs nm size range. 
Such broad particle size distribution and the appearance of 
large nanoparticle clusters are explained by the presence of 
PAP protein in the form oflarge biomolecular complexes or 
aggregates. The level of particle size distribution curve broad- 55 
erring can be quantitatively expressed using a polydispersity 
index (PdI). As shown in FIG. 6B, the PdI of assay solutions 
obtained from prostate cancer tissue lysates is clearly higher 
than the assay solutions of normal prostate and BPH tissue 
lysates. Interestingly, BPH tissue lysate assay solutions 60 
exhibit a narrower particle size distribution than normal tissue 
lysates, indicating that a different molecular mechanism is 
involved in BPH than in prostate cancer. Furthermore, it 
appears that more advanced prostate cancer with higher Glea-
son scores leads to a higher complexing level of PAP protein. 65 
To our best knowledge, this is the first time that such molecu-
lar profile differences were revealed from biological samples 
8 
and the potential link of such differences with cancer status of 
a biological system was discovered. 
3. Serum Protein and Protein Complex Detection and Pro-
filing for Diagnosis 
Using the third embodiment as illustrated in FIG. 3, we 
discovered some very interesting and intriguing molecular 
differences between serum samples with and without prostate 
cancer from both mice models and human donors. Prostate 
cancer is one of the most prevalent types of cancer in men. It 
is estimated that 217, 730 men will be diagnosed with and 
32,050 men will die of prostate cancer in 2010. Despite the 
enormous research efforts and investigations, early detection 
and diagnosis of prostate cancer has remained a significant 
challenge in medicine due to multiple complicated factors. 
PSA test, a test that measures the level of prostate specific 
antigen in blood, has been widely used in the United States in 
the last two decades for initial screening of prostate cancer. 
However, several recent studies have led to significant doubts 
on the efficacy of PSA test. Over-diagnosis and treatment of 
low-risk prostate cancer has serious and long-lasting side 
effect: 33% of the patients who receive radical prostatectomy 
treatment will suffer erectile dysfunction that cannot be rem-
edied by drugs such as Viagra. New biomarkers and test 
methods that can reliably distinguish prostate cancer from 
benign conditions and slow growing tumor from high risk 
cancer are of tremendous value in prostate cancer diagnosis 
and treatment. 
Three mice models were used for this study: one was 
orthotopically injected with a fast growing prostate cancer 
cell line PC3; one with a slow growing tumor cell line LnCaP; 
and a third group of mice injected only with PBS saline 
solution as control. FIG. 7 are the analysis results of mice 
serum samples. First, there is a dramatic difference in the 
"size" of the proteins or protein complexes adsorbed from 
serum to AuNPs (FIG. 7 A). The particle sizes from mice with 
large and fast growing tumor from PC3 cells are substantially 
smaller than that from normal healthy mice and mice with 
small and slow growing tumor from LnCaP cells. When the 
serum samples were diluted 10-fold and the serum protein 
adsorption assay was repeated, all samples exhibited similar 
particle size increase of 15-18 nm after the assay. 
The inventor then analyzed two target proteins: one is an 
abundant protein, mouse IgG, and another one is a well 
known cancer biomarker protein, VEGF (vascular endothe-
lial growth factor) according to the assay process as illus-
trated in FIG. 3. Again, some interesting differences were 
observed from these two assays. In the IgG assay, mice with 
small tumor grown from LnCaP cells exhibit higher level of 
IgG than the other two groups (FIG. 7B). In the VEGF assay, 
the normal healthy mice exhibit significantly higher level of 
AuNP-adsorbed VEGF than the mice with prostate cancer 
(FIG. 7C). Intrigued by the results observed from mice model 
study, we examined human serum samples obtained from 
subjects with prostate cancer. Three groups of human serum 
samples were studied: normal healthy donors; patients diag-
nosed with benign prostate hyperplasia (BPH); and patients 
diagnosed with prostate cancer (stages Tic to T3b ). From the 
VEGF assay, same difference was observed from the cancer 
versus non-cancer samples (normal donor and BPH patients) 
(FIG. 8): the non-cancer samples show higher level of AuNP-
adsorbed VEGF level than the prostate cancer samples. T-test 
analysis of the assay data gave a p-value of 0.001 for both 
diluted and undiluted human serum samples, indicating that 
the difference between cancer and non-cancerous samples 
was statistically significant. Furthermore, it was found from 
the assay that the AuNP-adsorbed VEGF level is also cancer 
stage-dependent: the more advanced prostate cancer exhibits 
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lower VEGF level than the early stage prostate cancer. Early 
stage prostate cancer such as Tlc shows similar VEGF level 
as healthy donors. In conclusion, the analysis of both mice 
model and human donor samples revealed that the amount of 
AuNP-adsorbed VEGF is decreased in cancer serum samples. 
This discovery could potentially lead to a new blood test with 
improved accuracy for prostate cancer detection. Further-
more, by screening other proteins or bimolecular targets 
using this assay, it is expected that additional protein or bio-
molecular biomarkers that are unique to cancer and other 10 
human diseases can be discovered. This new assay estab-
lished in our recent work may be used as a general tool for 
serum protein biomarker discovery. 
4. The Use ofBiomolecular Complexes as Biomarkers for 
Diagnostic Applications 15 
There are several types ofbiomarkers that have been iden-
tified so far and can be used for prostate cancer detection and 
diagnosis, particularly, for distinguishing prostate cancer 
from non-malignant conditions such as BPH: (1) The 
increased complexing level of PAP protein in tissue and 20 
bodily fluids; (2) The decreased level of VEGF protein in 
blood samples. This VEGF protein is referred to VEGF pro-
tein that is adsorbed to a nanoparticle through complexing 
with other proteins or biomolecules present in the blood 
serum; (3) The size of the biomolecule corona formed on a 25 
nanoparticle surface after non-specific adsorption ofbiomol-
ecules from a biological sample to the nanoparticles. 
The claims for biomarkers may be extended to the detec-
tion and diagnosis of other diseases and conditions: (1) The 
size of the biomolecule corona formed on a nanoparticle 30 
surface after a non-specific adsorption of biomolecules from 
a biological sample to the nanoparticles; (2) The size of the 
biomolecule corona formed on a nanoparticle surface after a 
specific binding of biomolecules from a biological sample to 
the baitingmolecule-conjugatednanoparticles; (3) Individual 35 
molecule component or biomolecule complexes of the bio-
molecule corona formed on a nanoparticle surface after a 
non-specific adsorption or specific binding of biomolecules 
from a biological sample to the nanoparticles that show sig-
nificant difference between diseased and non-diseased 40 
samples. 
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It should be borne in mind that all patents, patent applica-
tions, patent publications, technical publications, scientific 
publications, and other references referenced herein are 
hereby incorporated by reference in their entirety to the extent 
not inconsistent with the teachings herein. 
Reference to particular buffers, media, reagents, cells, cul-
ture conditions and the like, or to some subclass of same, is 
not intended to be limiting, but should be read to include all 
such related materials that one of ordinary skill in the art 
would recognize as being of interest or value in the particular 
context in which that discussion is presented. For example, it 
is often possible to substitute one buffer system or culture 
medium for another, such that a different but known way is 
used to achieve the same goals as those to which the use of a 
suggested method, material or composition is directed. 
It is important to an understanding of the present invention 
to note that all technical and scientific terms used herein 
unless defined herein, are intended to have the same meanin~ 
as commonly understood by one of ordinary skill in the art. 
The techniques employed herein are also those that are known 
to one of ordinary skill in the art, unless stated otherwise. For 
purposes of more clearly facilitating an understanding the 
invention as disclosed and claimed herein, the following defi-
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While a number of embodiments of the present invention 
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present invention need not be limited to best mode disclosed 
herein, since other applications can equally benefit from the 
teachings of the present invention. Also, in the claims, means-
plus-function and step-plus-function clauses are intended to 
4. Jans, H.; Liu, X.; Austin, L.; Maes, G.; Huo, Q. Dynamic 
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55 cover the structures and acts, respectively, described herein as 
performing the recited function and not only structural 
equivalents or act equivalents, but also equivalent structures 
or equivalent acts, respectively. Accordingly, all such modi-
fications are intended to be included within the scope of this 
60 invention as defined in the following claims, in accordance 
with relevant law as to their interpretation. 
What is claimed is: 
6. Bogdanovic, J.; Huo, Q. NanoDLSay: a new platform 65 
technology for biomolecular detection and analysis using 
gold nanoparticle probes coupled with dynamic light scat-
1. A method for detecting a biomolecule complex in a 
biological sample, said method comprising 
producing a first assay product by contacting a biological 
sample with a first nanoparticle probe, said first nano-
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particle probe comprising a nanoparticle bound to a first 
baiting molecule specific to a first target molecule of 
interest; 
contacting the first assay product with a second baiting 
molecule specific to a second target molecule of interest 
to produce a second assay product; and 
detecting by particle analysis for presence of nanoparticle 
probe bound to said first target molecule of interest, or 
for presence of said second target molecule of interest in 
said second assay product, or both, wherein if both, a 
complex of the first and second target molecules is 
present in the biological sample. 
10 
2. The method of claim 1, wherein particle analysis com-
p?ses determining a particle size change, an average particle 
size change, particle size distribution change, polydispersity 15 
change of the size distribution, or measurement-to-measure-
ment particle size variation, or combinations thereof. 
3. The method of claim 1, wherein said particle analysis is 
by dynamic light scattering analysis. 
4. The method of claim 1, wherein the particle analysis 20 
c.omprising determining a particle size change over nanopar-
t1cle probe-sample incubation time or over first target mol-
ecule concentration is used to obtain the binding constant or 
binding energy between the first baiting molecule and the first 
target molecule. 25 
5. The method of claim 4, wherein the binding constant or 
binding energy is obtained by fitting the binding data into a 
Langmuir adsorption model. 
6. The method of claim 1, further comprising determining 
whether a first target molecule is a monomer based on particle 30 
analysis. 
7. The method of claim 6, further comprising determining 
the quantity of a biomolecule complex based on particle 
analysis; or determining the size of a biomolecule complex 
based on particle analysis. 
8. The method of claim 7, further comprising utilizing a 
35 
quantity of a biomolecule complex to analyze a biological 
process, or for detection, diagnosis and/or prognosis of a 
disease; or utilizing the size of a biomolecule complex to 
analyze a biological process, or for detection, diagnosis and/ 
or prognosis of a disease. 
40 
9. The method of claim 8, wherein the disease is cancer. 
10. The method of claim 6, wherein the biomolecule com-
plex is a complex of PAP (prostatic acid phosphatase). 
11. The method of claim 1, wherein said biomolecule com-
plex comprises at least one first biomolecule or first biomol-
45 
ecule subunit associated with at least one other biomolecule. 
12 
12. The method of claim 11, wherein said at least one other 
biomolecule is the same as the first biomolecule or first bio-
molecule subunit. 
13. The method of claim 1, wherein said detecting com-
p?ses subjecting said second assay product to particle analy-
sis. 
14.A method for detecting a target molecule in a biological 
sample, said method comprising 
(a) obtaining a first assay product that has been produced 
by contacting a biological sample with a first nanopar-
ticle probe, said first nanoparticle probe comprising a 
nanoparticle bound to a first baiting molecule specific to 
a first target molecule of interest; 
(b) .subjecting said first assay product to a second nanopar-
t1cle probe comprising a second baiting molecule that is 
specific to a second target molecule of interest to pro-
duce a second assay product; and 
(c) detecting for presence of second nanoparticle probe 
bound to said second target molecule of interest in said 
second assay product, wherein if the second nanopar-
ticle probe bound to said second target molecule of 
interest is detected, the second target molecule of inter-
est is present in the biological sample; and further com-
prising detecting presence of first nanoparticle probe 
bound to said first target molecule of interest in said first 
assay product before step ( c ), wherein a biomolecule 
complex of said first and second target molecules of 
interest is detected based on a difference in size between 
said first assay product and said second assay product. 
15. A method for detecting at least one biomolecule in a 
biological sample, said method comprising obtaining a first 
assay product produced by contacting a biological sample 
with a nanoparticle, wherein said contacting forms a biomol-
ecule corona on the nanoparticle surface, and conducting 
particle analysis of the first assay product; and further com-
prising (i) using biomolecule corona size information for 
detection, diagnosis and/or prognosis of a disease by compar-
ing the biomolecule corona size information with size infor-
mation from a known sample, or (ii) contacting said first assay 
product with a baiting molecule that binds specifically to a 
target molecule of interest to form a second assay product, 
and detecting the presence and/or quantity of the target mol-
ecule of interest by particle analysis. 
16. The method of claim 15, wherein said analysis com-
prises size analysis of the biomolecule corona. 
* * * * * 
